Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1372-1378

  Shinozaki, Yukari ^a   Wang, Sen ^a   Miyazaki, Yoshiyuki ^a   Miyazaki, Kohji ^a   Yamada, Hisakata ^b   Yoshikai, Yasimobu ^b   Hara, Hiromitsu ^a   Yoshida, Hiroki ^a  

^a SAGA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

CTL Dendritic cells; IL 27; Melanoma; Tumor immunity

Indexed keywords

INTERLEUKIN 27; PEPTIDE DERIVATIVE; PERFORIN; ANGIOGENESIS INHIBITOR; CYTOKINE RECEPTOR; IL27RA PROTEIN, MOUSE; INTERLEUKIN 17; INTERLEUKIN 2; OVALBUMIN; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SPECIFICITY; CELL TRANSFER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; IMMUNE RESPONSE; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; WILD TYPE; ANIMAL; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; MELANOMA; MOUSE MUTANT; NEOPLASM; NEUROBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; DENDRITIC CELLS; INTERLEUKIN-17; INTERLEUKIN-2; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASMS; NEUROBLASTOMA; OVALBUMIN; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 60549117359     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24107     Document Type: Article

References (37)

1. Ghosh AK, Smith NK, Prendiville J, Thatcher N, Crowther D, Stem PL. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Eur cytokine Netw 1993;4:205-l1.
2. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
3. Atkins MB, Robertson MJ. Gordon M. Lotze MT, DeCoste M. DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
4. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain TFN-gamma induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
5. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998;4:1183-91.
6. Villarino AV, Huang E, Hunter CA. Understanding the pro-and anti-inflammatory properties of IL-27. J Immunol 2004; 173:715-20.
7. Yoshida H, Hamano S, Senaldi G, Covey T. Faggioni R, Mu S, Xia M, Wakeham AC, Nishina H, Potter J, Saris CJ, Mak TW. WSX-1 is required for the initiation of Thl responses and resistance to L. major infection. Immunity 2001; 15:569-78.
8. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. Role of IL-27/WSX-1 signaling for induc tion of T-Bet through activation of ST AT1 during initial Thl commitment. J Immunol 2003;170:4886-90.
9. Yoshida H, Hamano S, Miyazaki Y. The double identity of WSX-1 (I1-27R) as an initiator and attenuator of immune responses. Curr Immunol Rev 2005; 1:55-60.
10. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, Villarino AV, Huang Q, Yoshimura A, Sehy D, Saris CJ, O'shea JJ, et al Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006;7:937-45.
11. Batten M, Li J, Yi S, Kljavin KM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis bv suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-36.
12. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, Yoshimura A, Yoshida H. Two-sided roles of IL-27: induction of Thl differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 2006;177:5377-85.
13. Wang S, Miyazaki Y, Shinozaki Y, Yoshida H. Augmentation of antigen-presenting and Th 1-promoting functions of dendritic cells by WSX-1 (IL-27R) deficiency. J Immunol 2007;179:6421-8.
14. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshiraoto T. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-6.
15. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, Yoshimoto T. Antian- giogenic and antitumor activities of IL-27. J Immunol 2006:176:7317-24.
16. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006;66:6395-404.
17. Chiyo M, Shimozato O, Iizasa T, Fujisawa T, Tagawa M. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cvtokine genes in murine colon carcinoma cells. Anticancer Res 2004;24:3763-7.
18. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Halm C, Shaker-Weaver K, Malyguine A, Kastelein R, Wigginton JM. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T ceils. J Immunol 2004:173:7170-82.
19. Wang YQ, Ugai S, Shimozato O, Yu L, Kawamura K, Yamamoto H, Yamaguchi T, Saisho H, Tagawa M. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003;105:820-4.
20. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS, Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006;66:8887-96.
21. Hogquist KA, Jameson SC. Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
22. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201 -restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998;58:4895-901.
23. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185:453-9.
24. Hanada T, Yoshida H, Kato S, Tanaka K, Masutani K, Tsukada J, Nomura Y, Mimata H, Kubo M, Yoshimura A. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003;19:437-50.
25. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992:176:1693-702.
26. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68.
27. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-9.
28. Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2002;2:513-24.
29. Hamano S. Himeno K. Miyazaki Y. Ishii K, Yamanaka A, Takeda A. Zhang M, Hisaeda H, Mak TW, Yoshimura A, Yoshida H. WSX-1 Is Required for Resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003; 19:657-67.
30. Yamanaka A, Hamano S, Miyazaki Y, Ishii K, Takeda A, Mak TW, Himeno K, Yoshimura A, Yoshida H. Hyperproduction of Proinflammatory Cytokines by WSX-1-Deficient NKT Cells in Concanavalin A-Induced Hepatitis. J Immunol 2004;172:3590-96.
31. Holscher C, Holscher A, Ruckerl D, Yoshimoto T, Yoshida H, Mak T, Saris C, Ehlers S. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005;174:3534-44.
32. Miyazaki Y, Inoue H, Matsumura M, Matsumoto K, Nakano T, Tsuda M, Hamano S, Yoshimura A, Yoshida H. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1 -deficient mice. J Immunol 2005:175:2401-7.
33. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'shea JJ, Hunter CA. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007;8:1363-71.
34. Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, Saris CJ, Gran B, Ciric B, Rostami A. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-9.
35. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for Interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007:8:1380-9.
36. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52-8.
37. Tacken PJ, de Vries IJ, Torensraa R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7:790-802.